Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Shiraz University of Medical Sciences

Home Clinical Trial Sponsors and OrganizationsShiraz University of Medical Sciences

Shiraz University of Medical Sciences

ACTIVE

Iranwww.gsia.sums.ac.irPrivate10,001+ employeesEstablished: 1946-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

1523

170 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1946

Overview

Trial Phase Distribution

Phase

Trials

Share

Not Applicable

668

43.9%

Phase 3

367

24.1%

Phase 2

287

18.8%

Unknown

91

6.0%

Phase 1

50

3.3%

Phase 4

31

2.0%

Early Phase 1

16

1.1%

Trial Status Distribution

Terminated

1

0.1%

Recruiting

539

35.4%

Active, not recruiting

1

0.1%

Unknown

20

1.3%

Completed

793

52.1%

Enrolling By Invitation

1

0.1%

Not yet recruiting

168

11.0%

Clinical Trials

Trials sponsored by this organization (1523)

Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients

Not yet recruiting

Feb 2026400 participants

Immersive Virtual Reality Versus Manikin-Based Simulation for Cardiopulmonary Resuscitation Training

Oct 2025129 participants

Ticagrelore Alone Post PCI

Aug 20245,400 participants

Quality of Care and Welfare Services for Disabled Middle Older Adults in Iran Lebanon

Enrolling By Invitation

May 202486 participants

CTFFR and Prediction of Non-Significant CAD Lesions

Jan 2024250 participants

Efficacy of Education Via Phone-based Text Messaging (SMS) on Patients With Uncontrolled Hypertension

Not yet recruiting

Oct 2023200 participants

Saffron and Ulcerative Colitis

Not yet recruiting

May 202360 participants

The Effects of Action Observation Therapy (AOT) on Balance and Gait in Patients With Multiple Sclerosis.

Jan 202328 participants

Page 1 of 191

Approvals

No approval data available

News

Phase 3 Trial Shows Stem Cell Therapy Reduces Heart Failure Risk by 57% After Heart Attack

- The PREVENT-TAHA8 phase 3 trial demonstrated that intracoronary infusion of mesenchymal stem cells derived from Wharton's jelly significantly reduced heart failure incidence by 57% in STEMI patients. - At 3 years follow-up, only 5.74% of stem cell-treated patients developed heart failure compared to 16.08% in the standard care group. - The treatment also improved left ventricular ejection fraction by approximately 6% more than standard care and reduced heart failure readmissions by 78%. - Researchers attribute the benefits to the anti-inflammatory properties of mesenchymal stem cells, positioning this therapy as a viable adjunctive treatment for post-MI cardiac protection.

On this page

Overview
Clinical Trials1523
Approvals
News1

Back to Organizations